[go: up one dir, main page]

WO2021212049A3 - Anticorps monoclonaux anti-sars-cov-2 - Google Patents

Anticorps monoclonaux anti-sars-cov-2 Download PDF

Info

Publication number
WO2021212049A3
WO2021212049A3 PCT/US2021/027793 US2021027793W WO2021212049A3 WO 2021212049 A3 WO2021212049 A3 WO 2021212049A3 US 2021027793 W US2021027793 W US 2021027793W WO 2021212049 A3 WO2021212049 A3 WO 2021212049A3
Authority
WO
WIPO (PCT)
Prior art keywords
cov
sars
monoclonal antibodies
antibodies
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2021/027793
Other languages
English (en)
Other versions
WO2021212049A2 (fr
Inventor
Ali ELLEBEDY
Aaron SCHMITZ
Jackson TURNER
Wafaa AL SOUSSI
Michael Diamond
Daved FREMONT
James Brett CASE
Haiyan Zhao
John ERRICO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Washington University in St Louis WUSTL
Original Assignee
University of Washington
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, Washington University in St Louis WUSTL filed Critical University of Washington
Publication of WO2021212049A2 publication Critical patent/WO2021212049A2/fr
Publication of WO2021212049A3 publication Critical patent/WO2021212049A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des anticorps ou des fragments de liaison à l'antigène qui sont utiles pour le traitement des infections au coronavirus (p.ex., COVID-19 provqué par SARS-CoV-2). La présente invention concerne également diverses compositions pharmaceutiques et des méthodes de traitement du coronavirus à l'aide des anticorps ou des fragments de liaison à l'antigène.
PCT/US2021/027793 2020-04-17 2021-04-16 Anticorps monoclonaux anti-sars-cov-2 Ceased WO2021212049A2 (fr)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US202063011967P 2020-04-17 2020-04-17
US63/011,967 2020-04-17
US202063019846P 2020-05-04 2020-05-04
US63/019,846 2020-05-04
US202063024782P 2020-05-14 2020-05-14
US63/024,782 2020-05-14
US202063108850P 2020-11-02 2020-11-02
US63/108,850 2020-11-02
US202063114638P 2020-11-17 2020-11-17
US63/114,638 2020-11-17

Publications (2)

Publication Number Publication Date
WO2021212049A2 WO2021212049A2 (fr) 2021-10-21
WO2021212049A3 true WO2021212049A3 (fr) 2021-12-09

Family

ID=75870739

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/027793 Ceased WO2021212049A2 (fr) 2020-04-17 2021-04-16 Anticorps monoclonaux anti-sars-cov-2

Country Status (1)

Country Link
WO (1) WO2021212049A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023070310A1 (fr) * 2021-10-26 2023-05-04 中国科学院深圳先进技术研究院 Anticorps monoclonal entièrement humanisé anti-sars-cov-2 et son procédé de préparation ainsi que son application
WO2023077429A1 (fr) * 2021-11-05 2023-05-11 Shanghaitech University Anticorps trimères dirigés contre la protéine de spicule de sars-cov-2
EP4183800A1 (fr) * 2021-11-19 2023-05-24 Medizinische Hochschule Hannover Nouveaux anticorps neutralisants du sars-cov-2
AU2022420026A1 (en) * 2021-12-23 2024-07-11 Novavax, Inc. ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19
KR20250112314A (ko) * 2022-01-10 2025-07-23 페노믹 에이아이 항-콜라겐 삼중 나선 반복 함유 1(cthrc1) 항체 및 이를 사용하는 방법
CN114790240B (zh) * 2022-06-10 2023-06-06 郑州大学 SARS-CoV-2中和性单克隆抗体及应用
CN115925934B (zh) * 2022-07-26 2025-11-07 北京昌平实验室 一种稳定性提高的人源化单克隆抗体及其应用
CN116253796A (zh) * 2022-09-21 2023-06-13 三优生物医药(上海)有限公司 靶向冠状病毒的中和抗体、其抗原结合片段及其用途

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BALAMURUGAN SHANMUGARAJ ET AL: "Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19)", ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY, 1 March 2020 (2020-03-01), pages 10 - 18, XP055737131, Retrieved from the Internet <URL:http://apjai-journal.org/wp-content/uploads/2020/03/2.pdf> [retrieved on 20201006], DOI: 10.12932/AP-200220-0773 *
BIN JU ET AL: "Potent human neutralizing antibodies elicited by SARS-CoV-2 infection", 26 March 2020 (2020-03-26), XP055737104, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.03.21.990770v2.full.pdf> [retrieved on 20201006], DOI: 10.1101/2020.03.21.990770 *
CHUNYAN WANG ET AL: "A human monoclonal antibody blocking SARS-CoV-2 infection", BIORXIV, 12 March 2020 (2020-03-12), XP055725001, Retrieved from the Internet <URL:http://biorxiv.org/lookup/doi/10.1101/2020.03.11.987958> [retrieved on 20200825], DOI: 10.1101/2020.03.11.987958 *
JOYCE M. GORDON ET AL: "A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein", WWW.BIORXIV.ORG, 17 March 2020 (2020-03-17), pages 1 - 32, XP055819369, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.03.15.992883v1.full.pdf> [retrieved on 20210629], DOI: 10.1101/2020.03.15.992883 *
SHIBO JIANG ET AL: "Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses", TRENDS IN IMMUNOLOGY, vol. 41, no. 5, 2 April 2020 (2020-04-02), GB, pages 355 - 359, XP055694104, ISSN: 1471-4906, DOI: 10.1016/j.it.2020.03.007 *
SUN ZEHUA ET AL: "Potent neutralization of SARS-CoV-2 by human antibody heavy-chain variable domains isolated from a large library with a new stable scaffold", vol. 12, no. 1, 1 January 2020 (2020-01-01), US, pages 1 - 6, XP055819835, ISSN: 1942-0862, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531518/pdf/KMAB_12_1778435.pdf> DOI: 10.1080/19420862.2020.1778435 *
TAI WANBO ET AL: "Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine", CELLULAR & MOLECULAR IMMUNOLOGY, CHINESE SOCIETY OF IMMUNOLOGY, CH, vol. 17, no. 6, 19 March 2020 (2020-03-19), pages 613 - 620, XP037153214, ISSN: 1672-7681, [retrieved on 20200319], DOI: 10.1038/S41423-020-0400-4 *
XIAOLONG TIAN ET AL: "Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody", EMERGING MICROBES & INFECTIONS, vol. 9, no. 1, 3 February 2020 (2020-02-03), pages 382 - 385, XP055736759, DOI: 10.1080/22221751.2020.1729069 *

Also Published As

Publication number Publication date
WO2021212049A2 (fr) 2021-10-21

Similar Documents

Publication Publication Date Title
WO2021212049A3 (fr) Anticorps monoclonaux anti-sars-cov-2
WO2020039321A3 (fr) Anticorps anti-gdf15, compositions et procédés d&#39;utilisation
ZA202311412B (en) Anti-phf-tau antibodies and uses thereof
WO2019224711A3 (fr) Anticorps anti-cd33, anticorps bispécifiques anti-cd33/anti-cd3 et leurs utilisations
GEP20104922B (en) Antibodies to m-csf
WO2020160193A3 (fr) Composés et leurs utilisations
PH12021552903A1 (en) Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof
PH12022553035A1 (en) Anti-phf-tau antibodies and uses thereof
EA201491571A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
PH12023553159A1 (en) Anti-sirp-alpha antibodies
EA202091747A1 (ru) Составы антитела b7-h4
MX2023008423A (es) Anticuerpos anti-gremlin1 novedosos.
BR112024000744A2 (pt) Anticorpos de glicoprotéina spike anti-sars-cov-2 e fragmentos de ligação a antígeno
SA523451582B1 (ar) Ccr8 الأجسام المضادة لـ
WO2021207433A3 (fr) Épitopes d&#39;anticorps neutralisant le sars-cov-2
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.
EA202190807A1 (ru) Антитела к синуклеину
MX2024011805A (es) Nuevos anticuerpos anti-fgfr2
MX2023011339A (es) Anticuerpos anti-tau y usos de estos.
PH12020500662A1 (en) Anti-pfrh5 antibodies and antigen-binding fragments thereof
ZA202006216B (en) Antibodies targeting glycoprotein vi
MX2023012739A (es) Anticuerpos anti-gitr y usos de estos.
WO2023010065A3 (fr) Compositions et méthodes pour des anticorps anti-pacap
MX2025001042A (es) Formulaciones de anticuerpos contra tl1a
WO2018170236A9 (fr) Inhibiteurs de cdpk1, compositions et procédés associés

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21724438

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21724438

Country of ref document: EP

Kind code of ref document: A2